



Correction to: SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)

Jose Angel Garcia-Saenz¹ · Isabel Blancas² · Isabel Echavarria³ · Carmen Hinojo⁴ · Mireia Margeli⁵ · Fernando Moreno¹ · Sonia Pernas⁶ · Teresa Ramon y Cajal⁷ · Nuria Ribelles⁸ · Meritxell Bellet⁹

Published online: 5 June 2023
© The Author(s) 2023

Correction to: Clinical and Translational Oncology <https://doi.org/10.1007/s12094-023-03203-8>

In the sentence beginning “Therefore, tucatinib–lapatinib–capecitabine...” in this article, the text “tucatinib–lapatinib–capecitabine” should have read “tucatinib–trastuzumab–capecitabine” and the correct sentence should read as follows:

Therefore, tucatinib–trastuzumab–capecitabine may be a good option for patients treated with previous T-DM1 and/or T-Dxd [II, B].

The original article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s12094-023-03203-8>.

✉ Jose Angel Garcia-Saenz
jgsaenz@salud.madrid.org

Isabel Blancas
isabelblancas@hotmail.com

Isabel Echavarria
iechavarriadg@gmail.com

Carmen Hinojo
Carmen.hinojo@scsalud.es

Mireia Margeli
mmargeli@iconcologia.net

Fernando Moreno
fmorenoa@salud.madrid.org

Sonia Pernas
spernas@iconcologia.net

Teresa Ramon y Cajal
tramon@santpau.cat

Nuria Ribelles
nunuria.ribelles.sspa@juntadeandalucia.es

Meritxell Bellet
mbellet@vhio.net

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

- 1 Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), CIBERONC, Madrid, Spain
- 2 Hospital Universitario San Cecilio, Instituto de Investigación Biosanitaria de Granada (Ibs.Granada) and Medicine Department, Granada University, Granada, Spain
- 3 Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CIBERONC, Madrid, Spain
- 4 Hospital Universitario Marqués de Valdecilla, Santander, Spain
- 5 Institut Català d’Oncologia (ICO)-Badalona (Hospital Germans Trias i Pujol), B-ARGO (Badalona Applied Research Group in Oncology) and CARE (Translational Program in Cancer Research), Badalona, Spain
- 6 Institut Català d’Oncologia (ICO)-L’Hospitalet, Institut d’Investigació Biomedica de Bellvitge (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain
- 7 Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- 8 UGCI Oncología Intercentros, Hospitales Universitarios Regional y Virgen de la Victoria (IBIMA), Málaga, Spain
- 9 Hospital Universitario Vall D’Hebron, and Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain